Date: 2015-06-16
Type of information: Capital increase
Company: Affiris (Austria)
Investors: Santo Holding (Germany) MIG Verwaltungs AG (Germany)
Amount: € 10 million
Funding type: capital increase
Planned used: The new capital allows the company to further advance its AFFITOME®-technology for the prevention and therapy of chronic illnesses. Recently, AFFIRIS presented Phase 1 data on its Parkinson’s vaccine candidate PD01. PD01A was the first α-synuclein targeting drug candidate that successfully completed a phase 1 study. α-synuclein is a protein which plays a role in the pathological processes of neurodegenerative diseases such as Parkinson’s. The program enjoys the support from The Michael J. Fox Foundation.
Others: * On June 16, 2015, Affiris has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the Supervisory Board as of 18 May 2015 and replaces Dr. Walter Schmidt who has decided to leave the Supervisory Board. Mag. Vera Bürger and Claudia Juno have been appointed by the employees to join the Supervisory Board. In an extraordinary shareholders meeting on 18 May 2015 the shareholders of the company have agreed to a capital increase of € 10 million. The new shares have equally been subscribed by the two major investors of the company, Santo Holding – the family office of the Strüngmann family – and the MIG Funds represented by MIG Verwaltungs AG. The shareholders also elected Prof. Dr. Christoph Huber as member of the Supervisory Board. He will replace Dr. Walter Schmidt who has decided to leave the Supervisory Board. Walter Schmidt co-founded Affiris eleven years ago and profoundly influenced the company until his resignation from operational responsibilities this past January. Affiris has been able to attract funding of approx. € 120 million to date, half of which comes from license income and government grants.
Therapeutic area: Neurodegenerative diseases
